Related Experiment Video
Updated: May 14, 2026
12:28
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
Relationship between plasma analytes and SPARE-AD defined brain atrophy patterns in ADNI
Jon B Toledo1, Xiao Da, Priyanka Bhatt
1Department of Pathology & Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Plos One
|February 15, 2013
Summary
New Alzheimer's disease (AD) research links plasma biomarkers for stress and inflammation to AD-like brain atrophy. These findings correlate with clinical changes and cerebrospinal fluid biomarkers.
Area of Science:
- Neuroscience
- Biochemistry
- Medical Biomarkers
Background:
- Alzheimer's disease (AD) is linked to inflammatory and metabolic pathways.
- Multi-analyte panels now enable large-scale molecular studies in well-characterized cohorts.
- Identifying specific molecules can elucidate affected pathways in AD.
Purpose of the Study:
- To investigate the relationship between plasma biomarkers and AD-like brain atrophy patterns.
- To correlate plasma biomarkers with clinical changes and cerebrospinal fluid (CSF) biomarkers in AD.
Main Methods:
- Utilized the Human DiscoveryMAP panel for plasma biomarker analysis.
- Assessed AD-like brain atrophy using the SPARE-AD index from MRI data in the ADNI cohort.
- Analyzed correlations between 818 subjects' plasma biomarkers, SPARE-AD scores, and CSF tau/Aβ measurements using adjusted models.
Main Results:
- Plasma macrophage inhibitory protein-1α and insulin-like growth factor binding protein 2 significantly associated with brain atrophy.
- Plasma cortisol showed an inverse association with processing speed.
- Cortisol and chromogranin A associations with atrophy were not significant after adjusting for CSF biomarkers.
Conclusions:
- Stress (cortisol) and insulin responses are linked to AD-like brain atrophy.
- Cytokines involved in inflammatory cell recruitment correlate with AD brain atrophy patterns.
- These plasma biomarkers show potential for correlating with clinical changes and CSF biomarkers in AD.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...